RecruitingPhase 2

Ketamine for Methamphetamine Use Disorder

United States120 participantsStarted 2024-09-11

Plain-language summary

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be 18 to 65 years old
✓. Be able to sufficiently understand, speak, and read English
✓. Be interested in reducing or stopping methamphetamine use
✓. Meet criteria for methamphetamine use disorder
✓. Use acceptable methods of contraception during participation in the study

Exclusion criteria

✕. Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
✕. Be currently in jail, prison, or inpatient overnight facility as required by court of law
✕. Have upcoming surgery planned or scheduled
✕. Be currently pregnant, breastfeeding, or planning on conception, if biologically female

What they're measuring

Treatment Response

Timeframe: 2 weeks

Trial details

NCT IDNCT06496750

SponsorUniversity of Texas Southwestern Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-18

Contact for this trial

Angela Casey-Willingham

214-648-4689 Angela.Casey-Willingham@UTSouthwestern.edu

View on ClinicalTrials.gov More Substance Use Disorders trials